Astrazeneca (AZN) Current Assets (2009 - 2026)

Astrazeneca (AZN) has reported Current Assets for 18 consecutive years, with $29.6 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 13.29% year-over-year to $29.6 billion; the TTM figure through Mar 2026 stood at $29.6 billion (up 13.29% YoY), while the FY2025 annual figure was $28.7 billion, up 11.21% from the prior year.
• Current Assets came in at $29.6 billion for Q1 2026 at Astrazeneca, up from $28.7 billion in the prior quarter.
• The five-year high for Current Assets was $29.9 billion in Q3 2025, with the low at $20.2 billion in Q3 2022.
• Average Current Assets over 5 years is $24.9 billion, with a median of $25.1 billion recorded in 2023.
• The largest YoY upside for Current Assets was 52.99% in 2022 against a maximum downside of 24.23% in 2022.
• Year by year, Current Assets stood at $22.6 billion in 2022, then gained by 10.89% to $25.1 billion in 2023, then gained by 3.09% to $25.8 billion in 2024, then gained by 11.21% to $28.7 billion in 2025, then gained by 3.1% to $29.6 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $29.6 billion, $28.7 billion, and $29.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.